JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258776

Human ACOT9 (Acyl-CoA Thioesterase 9) knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

ACOT9 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1.

View Alternative Names

ACOT9_HUMAN, Acyl-CoA thioester hydrolase 9, Acyl-CoA thioesterase 9, Acyl-coenzyme A thioesterase 9, Acyl-coenzyme A thioesterase 9, mitochondrial, CGI 16, mitochondrial

1 Images
Sanger Sequencing - Human ACOT9 (Acyl-CoA Thioesterase 9) knockout HeLa cell lysate (AB258776)
  • Sanger seq

Unknown

Sanger Sequencing - Human ACOT9 (Acyl-CoA Thioesterase 9) knockout HeLa cell lysate (AB258776)

Homozygous : 1 bp insertion in exon1

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1.

Disease

Adenocarcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258776-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human ACOT9 knockout HeLa cell lysate", "number":"AB258776-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ACOT9
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Acyl-CoA Thioesterase 9 (ACOT9) sometimes referred to as anti-CoA functions mechanically by hydrolyzing CoA esters into free fatty acids and CoA-SH playing a role in lipid metabolism. ACOT9 has a molecular mass of approximately 70 kDa. The expression of ACOT9 occurs in various tissues with higher levels observed in the liver and kidney contributing to the regulation of fatty acid and CoA concentrations within the cells.
Biological function summary

ACOT9 participates in the regulation of lipid metabolism and energy homeostasis. It does not form part of a known complex but performs a stand-alone role in converting activated fatty acids into their free form and CoA. This process contributes to the balance between synthesis and degradation of lipids impacting energy production and storage. ACOT9's action influences cellular metabolic states and can adapt them depending on the energy requirement of the organism.

Pathways

ACOT9 plays an important role in the peroxisomal and mitochondrial fatty acid oxidation pathways. In these pathways it interacts with enzymes such as Acyl-CoA oxidase and Carnitine palmitoyltransferase I facilitating the breakdown of long-chain fatty acids. ACOT9's hydrolytic activity helps reduce the build-up of acyl-CoA intermediates which is essential for maintaining cellular energy balance and supporting metabolic flexibility during fasting or exercise.

ACOT9 has been linked to metabolic syndromes including obesity and non-alcoholic fatty liver disease (NAFLD). Its modulation can influence the aberrant accumulation of lipids leading to these conditions. ACOT9's activity also connects it with proteins such as AMP-activated protein kinase (AMPK) in the regulation of energy homeostasis which is disrupted in metabolic disorders. Understanding the role of ACOT9 in these diseases may provide insights into therapeutic targets for managing metabolic imbalances.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com